Company intelligence / Profile preview
Xalud Therapeutics
New York City, New York, United Statesxaludthera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xalud has completed a Phase 2b trial for XT-150 in osteoarthritis of the knee and has an ongoing Phase 1/2a trial in facet joint syndrome. The company has also conducted preclinical studies in ALS, MS, neuropathic pain, and uveitis. In December 2021, XT-150 received FDA Fast Track designation for the treatment of pain associated with osteoarthritis of the knee.
- Therapeutic areas
- DermatologyRheumatologyOphthalmologyNeurology
- Modalities
- Non-viral gene therapyplasmid DNA (pDNA) gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Xalud Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xalud Therapeutics.